Peregrine Pharmaceuticals Inc.

Paul Lytle has served as Chief Financial Officer since August 2002. Mr. Lytle oversees Finance & Accounting, SEC Reporting, Investor Relations, Human Resources and Information Technology. Mr. Lytle started with Peregrine in March 1997 as Corporate Controller and has held positions of increasing responsibility at the company. Mr. Lytle was promoted to Vice President of Finance and Accounting and was elected as the company's Corporate Secretary in 2000. Mr. Lytle has been responsible for the development and implementation of numerous technology initiatives, increasing the company's efficiency in many areas, including finance. Mr. Lytle implemented a new interfaced accounting system and oversaw the installation of company networks and management information systems. During his tenure, Peregrine has raised over $100 million in equity financing from the public markets. Prior to joining Peregrine, Mr. Lytle worked for Deloitte & Touche LLP. Mr. Lytle holds a BS in Business Administration from the California State University at Long Beach and is a certified public accountant in the State of California and a member of the American Institute of Certified Public Accountants.

Richard Richieri has over ten years of experience in the biologics industry manufacturing proteins and antibodies. At Peregrine, as director of manufacturing, he was responsible for process development and manufacture of clinical trial materials. At Avid Bioservices, Mr. Richieri is responsible for all manufacturing including process development and facilities. Prior to joining Peregrine, he worked at Xoma Corporation where he was responsible for large-scale manufacturing and mammalian cell culture process development. Mr. Richieri received his Bachelor's degree from University of California, Los Angeles (UCLA) in Chemical Engineering and his M.S. from University of California, San Diego (UCSD) studying the dependency of antibody production on cell cycle kinetics. Mr. Richieri is licensed as an Exemptee Pharmacist by the Board of Pharmacy State of California.

David King, Vice President of Business Development, has over 20 years of commercial experience in the biopharmaceutical industry, including sales, marketing and extensive business development experience. His expertise in this area has led to the completion of significant corporate partnering deals with industry partners. He has identified, negotiated and closed a wide range of transactions including out-license, in-license, co-promotion and joint development and marketing agreements. Mr. King has an extensive network of contacts at biopharmaceutical companies in North America, Europe and Asia. Mr. King was formerly employed with Medinox, Inc., in San Diego, where he served as Vice President, Corporate Development. Previously, Mr. King held several executive and management level positions at various pharmaceutical companies, including Maxim Pharmaceuticals, DepoTech Corporation (now SkyePharma Ltd.), and Glaxo Inc. (now GlaxoSmithKline). He began his pharmaceutical industry career in sales and marketing for Stuart Pharmaceuticals (now AstraZeneca). Mr. King holds a bachelor's degree in Business Administration from Goshen College in Goshen, IN.

Shelley Fussey joined Peregrine as Vice President, Intellectual Property in February 2005. Dr. Fussey will play a key role in Peregrine's US and international patenting, patent analysis and patent defense. An expert in European opposition procedures, portfolio analysis and counseling in the biotechnology arena, Dr. Fussey's expertise includes patent strategy for technologies...

John L. Quick has been associated with Peregrine and Avid since mid-2004 as a consultant on quality and regulatory compliance. He is founder of Quick & Associates a consulting firm devoted to quality, regulatory compliance and new product development consulting. Mr. Quick retired from Baxter International after a 37 year career with the company with responsibility for new product development and quality management . In 1998, Mr. Quick was appointed corporate vice president quality/regulatory compliance responsible for all worldwide quality and regulatory compliance at Baxter, reporting to the Chairman and CEO, a position he held until his retirement. Mr. Quick is immediate past Chairman of the Board of the Lincoln Foundation for Performance Excellence and is Vice Chairman of the Board of Methodist Hospital of Chicago and its parent corporation. Mr. Quick has an undergraduate degree in Chemistry from Indiana University and an MBA from the Northwestern J.L. Kellogg Graduate School of Management. He holds three issued patents and has made numerous industry presentations on the subject of quality and regulatory compliance.

Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.

Thomas A. Waltz, MD, is senior consultant in neurosurgery and former head of the Division of Neurosurgery of Scripps Clinic in La Jolla, California. Dr. Waltz was chairman and CEO of the Scripps Clinic from 1991 2000, president of the Scripps Clinic Medical Group from 1990 2000, and staff neurosurgeon of the Clinic from 1977 to the present time. Dr. Waltz received his undergraduate degree from the University of Cincinnati and graduated from Vanderbilt University School of Medicine. He was a resident in neurosurgery at Baylor School of Medicine in Houston and held fellowships at the National Hospital of Neurological Diseases in London and in neuropathology at Oxford. Dr. Waltz also served with the United States Air Force as captain and flight surgeon. He is widely published in neurosurgery and lectures both nationally and internationally.

Mr. Pohl served as Chairman of the Board, President and CEO of Patriot Scientific Corporation from June 2005 to June 2007, and was a member of its board of directors from April 2001 until February 2008. Mr. Pohl also served as an officer of Patriot from January 2001 to March 2002. He is currently Chairman of the Board of Wellness.com, Inc., a privately held Internet enterprise, and two of its affiliates. Mr. Pohl was in the private practice of law counseling business clients from 1997 to 2005, and from 1995 to 1996 was Special Counsel to the Ohio Attorney General regarding entrepreneurial investments by state employee pension funds. Previously, he was a Senior Attorney with Jones Day Reavis & Pogue, a large U.S. law firm, and held positions as a senior officer and general counsel in large financial services corporations that developed assets of more than $1 billion. Mr. Pohl is a member of the Corporate Directors Forum of San Diego, the Intellectual Property Law and Business Law Sections of the State Bar of California, has served as a member of the Board of Governors of the Corporate Counsel Section of the Ohio State Bar Association, and is an Emeritus member of the Board of Directors of the American Financial Services Association, Washington, D.C. Mr. Pohl earned a Juris Doctor degree from the Ohio State University College of Law, and also holds a B.S. in Administrative Sciences from Ohio State.

Eric S. Swartz has served as a director of Peregrine since 1999. Mr. Swartz is the founder and President of Roswell Capital Partners, LLC and previous founder and President of Equiplace Securities, LLC (formerly Swartz Investments, LLC), which he started in 1993. Prior to 1993, Mr. Swartz was a Vice President at Bear Stearns & Co. specializing in foreign institutional equity investments in U.S. securities. Prior to that, Mr. Swartz was a Vice President with Oppenheimer & Co., where he was involved in overseas placements of equity and debt for institutions in Germany, Austria, Switzerland, France, Australia, and New Zealand. Mr. Swartz has approximately 20 years of experience in the securities business.